Build-to-Buy Deals: A Game-Changer in Pharmaceutical Investment
Monday, 26 August 2024, 04:15
Exploring Build-to-Buy in Pharma
Build-to-buy is a transformative strategy in the pharmaceutical sector that allows major companies to maintain flexibility while securing future assets. In this context, Jerel Davis from Versant provides insights on how these arrangements pave the way for effective partnerships.
Advantages of Build-to-Buy Strategies
- Strategic Flexibility: Major firms can adapt their investment based on market needs.
- Reduced Risk: Minimized immediate financial commitment while retaining acquisition options.
- Focused Development: Startups can concentrate on innovation while potential partners evaluate their progress.
Impact on Pharma Investments
According to Davis, build-to-buy agreements create a fertile ground for lucrative investments in pharmaceuticals. These deals not only enhance innovation but also encourage a collaborative spirit between smaller startups and larger corporations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.